Recent Biotechnology Acquisitions
Acquisition Volume in Biotechnology by Year
Last 5 years
This page highlights recent acquisitions in the Biotechnology sector where buyers have added pipelines, platform technologies, manufacturing capabilities, and specialist teams. Notable transactions include Axol Bioscience acquiring Newcells’ ophthalmology business, Illumina acquiring SomaLogic, and Sensei Biotherapeutics acquiring Faeth Therapeutics.
Across the listed events buyers range from large strategics to PE and growth investors. Common themes are capability tuck‑ins (proteomics, mRNA design, ophthalmology models), CDMO and bioconjugation expansion, and consolidation of preclinical and translational services across geographies such as the United States, the United Kingdom, France and Canada. Recurring buyers on the page include names like Ampersand Capital Partners, Eli Lilly and Company, and Pfizer Inc.
What Stands Out
- Strategic buyers are prioritizing platform and pipeline add‑ons: examples include Illumina adding proteomics with SomaLogic and Sobi adding a Phase 3 gout asset from Arthrosi Therapeutics.
- Private equity and growth investors are active in specialty CDMO and agri/industrial biotech: for example, Gannet BioChem with Ampersand Capital Partners acquired Laysan Bio, and KKR led a follow‑on investment in Sylvan.
- Technology and capability themes recur: proteomics, mRNA/AI design and analytics, ophthalmology iPSC models, bioconjugation/PEG reagents, gene delivery platforms (Super piggyBac), and integrated preclinical/translational services.
- Geographic spread centers on U.S. hubs (Massachusetts, California, Colorado, Alabama, Kentucky) with notable transactions in the UK, France and Quebec, Canada.
- Deal structures vary: cash plus earnouts, stock‑for‑stock transactions, debt facilities combined with equity, and concurrent private placements are all represented on the page.
-
Eli Lilly Acquires Centessa Pharmaceuticals for Up to $7.8 Billion to Expand Sleep Disorder PipelineMarch 31, 2026
- Buyer
- Eli Lilly and Company
- Target
- Centessa Pharmaceuticals
- Industry
- Biotechnology
- Location
- United Kingdom
- Type
- Buyout
Eli Lilly and Company has announced it will acquire Centessa Pharmaceuticals in a deal valued at about $6.3 billion upfront, with additional contingent payments that could bring the total value to around $7.8 billion. The acquisition is designed to strengthen Lilly’s neuroscience and sleep medicine portfolio by adding Centessa’s orexin receptor 2 (OX2R) agonist pipeline, including cleminorexton.
-
March 27, 2026
- Buyer
- Novartis
- Target
- Excellergy
- Industry
- Biotechnology
- Type
- Buyout
Novartis announced it entered into an agreement to acquire Excellergy, a private biotechnology company developing next-generation anti-IgE therapies, in a deal valued at up to $2 billion including upfront and milestone payments. The acquisition is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.
-
March 27, 2026
- Buyer
- Otsuka Pharmaceutical
- Target
- Transcend Therapeutics
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Otsuka Pharmaceutical entered into an agreement to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion. Under the terms, Otsuka will pay $700 million upfront at closing and up to $525 million in contingent payments tied to future sales milestones, with expected closing in Q2 2026.
-
Gilead Sciences to Acquire Ouro Medicines for $1.675B Upfront to Advance Autoimmune T Cell TherapiesMarch 27, 2026
- Buyer
- Gilead Sciences
- Target
- Ouro Medicines
- Industry
- Biotechnology
- Type
- Buyout
Gilead Sciences entered into a definitive agreement to acquire Ouro Medicines, a clinical-stage biotech focused on T cell engager therapies for autoimmune diseases, in a deal valued at $1.675 billion upfront with up to $500 million in milestone payments. The acquisition adds OM336 (gamgertamig), a BCMAxCD3 bispecific T cell engager currently in Phase 1/2 trials, to strengthen Gilead’s inflammation and immunology portfolio.
-
March 26, 2026
- Buyer
- Lunai Bioworks, Inc. (NASDAQ: LNAI)
- Target
- Clemann Group, SAS (or its assignee) — BBB delivery technology and CNS Alzheimer’s drug assets
- Seller
- Clemann Group, SAS
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Lunai Bioworks executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and CNS Alzheimer’s drug assets from the Clemann Group, SAS (or its assignee). The deal is structured as Series B Convertible Preferred with a fixed $1.50 conversion price and is intended to strengthen Lunai’s CNS Alzheimer's pipeline while enabling development across other CNS disorders.
-
March 26, 2026
- Buyer
- Pulmatrix, Inc.
- Target
- Eos SENOLYTIX, Inc.
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Pulmatrix and Eos SENOLYTIX announced a definitive merger agreement under which Pulmatrix will acquire Eos. The combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker EOSX, with the deal funded alongside $19 million of concurrent private financings to advance Eos’s MitoXcel platform and lead candidate PTC-2105 for sarcopenia and sarcopenic obesity.
-
March 26, 2026
- Buyer
- Merck
- Target
- Terns Pharmaceuticals
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Merck has agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion to accelerate its expansion in blood cancer treatments, particularly chronic myeloid leukemia. The deal centers on Terns’ lead asset, TERN-701, an investigational oral allosteric BCR::ABL1 inhibitor currently in Phase 1/2, with the transaction expected to close in the second quarter of 2026 subject to approvals.
-
March 24, 2026
- Target
- Apimeds Pharmaceuticals US, Inc. (APUS), MindWave Innovations Inc., Inscobee Inc., Apimeds Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Divestiture
Apimeds Pharmaceuticals US, through its wholly owned subsidiary MindWave Innovations, said Inscobee and its wholly owned subsidiary Apimeds Inc. filed an Amendment to Schedule 13D to effect a hostile takeover of the board by written consent. The company alleges Inscobee removed the existing directors and installed replacements without authorization under an irrevocable proxy and lock-up agreement tied to the merger with MindWave, and it is preparing an emergency action in Delaware Court of Chancery.
-
March 7, 2026
- Buyer
- MGI Tech
- Target
- STOmics, CycloneSEQ
- Industry
- Biotechnology
- Location
- China
- Type
- Buyout
MGI Tech announced the acquisition of STOmics and CycloneSEQ to integrate long-read sequencing, short-read sequencing, and spatial omics technologies into a unified platform. The deal brings STOmics’ Stereo-seq spatial multi-omics tech and CycloneSEQ’s nanopore-based long-read sequencing systems in-house, supporting MGI’s “SEQALL+GLI+Omics” strategy and a more comprehensive end-to-end offering for researchers.
-
March 5, 2026
- Buyer
- Rallybio Corporation
- Target
- Candid Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Rallybio Corporation entered into a definitive agreement to acquire clinical-stage biotechnology company Candid Therapeutics in a merger transaction. The combined company will operate as Candid Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol CDRX, with the deal targeted to close in mid-2026 subject to customary conditions and approvals. Concurrently, Candid arranged an oversubscribed private financing of more than $505 million from a syndicate of healthcare institutional investors and mutual funds, expected to fund operations through 2030.
-
March 5, 2026
- Buyer
- Solabia, Astorg, TA Associates
- Target
- Mibelle Biochemistry, Seqens' Botanical Actives and In-Vitro Diagnostics Activity, Xebios Group
- Industry
- Biotechnology
- Location
- France
- Type
- Addon
Solabia, a Paris-headquartered biotech platform focused on natural active ingredients and diagnostics solutions, has agreed to acquire three complementary businesses as part of its international expansion strategy. The acquisitions include Switzerland-based Mibelle Biochemistry, France-based Seqens' Botanical Actives and In-Vitro Diagnostics activity, and Germany/Netherlands-based Xebios Group.
-
March 5, 2026
- Buyer
- Esperion Therapeutics
- Target
- Corstasis Therapeutics
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Esperion Therapeutics announced it has entered into a definitive agreement to acquire Corstasis Therapeutics for an upfront cash payment of $75 million, with potential milestone payments of up to $180 million. The deal is expected to add Enbumyst (bumetanide nasal spray) to Esperion’s cardiovascular portfolio, leveraging its commercial infrastructure to expand its cardiovascular franchise.
-
February 26, 2026
- Buyer
- Asahi Kasei
- Target
- Aicuris Anti-infective Cures AG
- Industry
- Biotechnology
- Location
- Germany
- Type
- Buyout
Asahi Kasei entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a German biopharmaceutical company, for approximately €780 million (about $919 million). The deal is expected to close in the first quarter of fiscal 2026, subject to customary conditions, and is intended to strengthen Asahi Kasei’s specialty pharmaceutical platform in severe infectious diseases.
-
February 23, 2026
- Buyer
- Axol Bioscience
- Target
- Newcells Biotech (ophthalmology business)
- Seller
- Newcells Biotech
- Industry
- Biotechnology
- Location
- Tyne and Wear, United Kingdom
- Type
- Divestiture
Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.
-
February 21, 2026
- Buyer
- Gilead Sciences
- Target
- Arcellx, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Gilead Sciences entered into a definitive agreement to acquire Arcellx, Inc. for $115 per share in cash plus a contingent value right of $5 per share, implying an equity value of about $7.8 billion. The deal is designed to give Gilead full control of Arcellx’s anito-cel (anito-cabtagene autoleucel) BCMA-directed CAR T therapy, eliminating profit-sharing and related payments while accelerating development and commercialization.
-
February 18, 2026
- Buyer
- Sensei Biotherapeutics, Inc.
- Target
- Faeth Therapeutics, Inc.
- Seller
- Faeth Therapeutics equityholders
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Sensei Biotherapeutics (Nasdaq: SNSE) has acquired clinical-stage Faeth Therapeutics in a stock-for-stock transaction that brings Faeth's lead oncology asset PIKTOR into Sensei's pipeline. Concurrently Sensei raised approximately $200 million in a private placement of Series B non-voting convertible preferred stock from a syndicate of institutional life-sciences investors to advance PIKTOR through Phase 2 topline data and initiate a Phase 1b breast cancer trial.
-
February 9, 2026
- Buyer
- Eli Lilly and Company
- Target
- Orna Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Eli Lilly and Company has signed a definitive agreement to acquire Orna Therapeutics, valuing the deal at up to $2.4 billion. The acquisition is intended to expand Lilly’s genetic medicine and in vivo cell engineering capabilities, particularly for advancing in vivo CAR-T therapies using Orna’s circular RNA and lipid nanoparticle (LNP) platform.
-
- Buyer
- XOMA Royalty Corporation
- Target
- Generation Bio Co. (Generation Bio)
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
XOMA Royalty Corporation completed its previously announced tender offer to acquire all outstanding shares of Generation Bio common stock for $4.2913 per share in cash, plus one non-tradeable contingent value right (CVR). Following the tender offer, a subsidiary (XRA 7 Corp.) merged with and into Generation Bio, making Generation Bio a wholly owned subsidiary of XOMA Royalty.
-
February 4, 2026
- Buyer
- DT Cloud Star Acquisition Corporation
- Target
- PrimeGen US, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
PrimeGen US, Inc. entered into a definitive business combination agreement with DT Cloud Star Acquisition Corporation (a publicly traded SPAC), implying an equity value of approximately $1.5 billion. The transaction is expected to provide access to public markets capital to advance PrimeGen US’s stem cell and exosome therapies, with an anticipated closing in the second half of 2026 subject to approvals and customary closing conditions.
-
February 3, 2026
- Buyer
- Cycle Group Holdings Limited, AT2B, Inc.
- Target
- Applied Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Cycle Group Holdings Limited, through AT2B, Inc., completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. Applied is a clinical-stage biopharmaceutical company developing govorestat, an aldose reductase inhibitor for CNS rare metabolic diseases.
-
January 29, 2026
- Buyer
- Demeetra AgBio
- Target
- Hera BioLabs
- Industry
- Biotechnology
- Location
- Kentucky, United States
- Type
- Buyout
Demeetra AgBio has completed the acquisition and full integration of Hera BioLabs, consolidating commercial rights to the hyperactive Super piggyBac transposase platform under Demeetra. The deal brings Hera’s in vitro services into Demeetra’s R&D, winds down Hera’s in vivo services, and positions Demeetra as the definitive commercial licensor for Super piggyBac across research, development, and biomanufacturing use cases.
-
January 29, 2026
- Buyer
- Eclipse Bioinnovations (Eclipsebio)
- Target
- Terrain Bio
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Eclipse Bioinnovations (Eclipsebio) has acquired Terrain Bio to integrate Terrain's AI/ML RNA design models and R&D-scale mRNA manufacturing analytics into Eclipsebio's sequencing-based validation platforms. The deal creates an end-to-end Design, Make, Test platform intended to accelerate RNA therapeutic development by connecting computational design directly to experimental feedback.
-
January 28, 2026
- Buyer
- XenoTherapeutics, Inc., Xeno Acquisition Corp.
- Target
- Repare Therapeutics Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
XenoTherapeutics, Inc. and Xeno Acquisition Corp. acquired all outstanding shares of Repare Therapeutics Inc. via a statutory plan of arrangement. The deal was approved by Repare shareholders in January 2026 and the acquisition was completed with a per-share cash payment of approximately US$2.20 plus contingent value rights.
-
January 23, 2026
- Buyer
- GSK
- Target
- RAPT Therapeutics
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
GSK signed a definitive agreement to acquire RAPT Therapeutics for an aggregate equity value of about $2.2 billion, expanding its Respiratory, Immunology & Inflammation pipeline. The deal adds ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylaxis of food-allergy reactions.
-
January 22, 2026
- Buyer
- Gannet BioChem, Ampersand Capital Partners
- Target
- Laysan Bio
- Industry
- Biotechnology
- Location
- Alabama, United States
- Type
- Addon
Gannet BioChem, a PE-backed specialty CDMO, has acquired Laysan Bio, a maker of activated polyethylene glycol (PEG) reagents based in Arab, Alabama. The add-on expands Gannet BioChem's activated polymer and bioconjugation capabilities, strengthening its ability to support partners from early development through GMP manufacturing.
-
January 22, 2026
- Buyer
- KKR, TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee, Novo Holdings
- Target
- Sylvan
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Growth capital
KKR has completed an additional investment in Sylvan, a global mushroom spawn and fungal biotechnology company, with participation from TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee and a follow-on from Novo Holdings. The funding will support Sylvan’s expansion—increasing production capacity, strengthening R&D, developing new product categories and deeper growth across Asian markets—while KKR remains the company’s majority investor.
-
January 20, 2026
- Buyer
- EQT Life Sciences (LSP Dementia Fund), Gimv, Fountain Healthcare Partners, LifeArc, Carma Fund, Modi Ventures, Andera Partners, LBBW
- Target
- Exciva (EXCIVA GmbH)
- Industry
- Biotechnology
- Location
- Baden-Württemberg, Germany
- Type
- Growth capital
EQT Life Sciences (via its LSP Dementia Fund) and Gimv co-led a €51 million Series B in German clinical-stage biopharmaceutical company Exciva to fund a Phase 2 trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease. Additional participants included Fountain Healthcare Partners, LifeArc, Carma Fund, Modi Ventures, Andera Partners, LBBW and returning investors; proceeds will support multinational Phase 2 studies across the EU, United States and Canada.
-
January 20, 2026
- Buyer
- Taconic Biosciences, Inc.
- Target
- TransCure bioServices SAS
- Industry
- Biotechnology
- Location
- Haute-Savoie, France
- Type
- Buyout
Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.
-
January 16, 2026
- Buyer
- Zydus Lifesciences Limited, Zylidac Bio LLC
- Target
- Agenus Inc.
- Seller
- Agenus Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Zydus Lifesciences Limited has completed purchase agreements with Agenus Inc. to acquire Agenus' biologics manufacturing facilities and operations in Emeryville and Berkeley, California, and has established a U.S. CDMO subsidiary, Zylidac Bio LLC, to operate the assets. The deal includes exclusive manufacturing arrangements for Agenus' Phase 3 immuno-oncology candidates (botensilimab and balstilimab), exclusive commercialization rights for those assets in India and Sri Lanka, and an equity investment in Agenus via Zynext Ventures; regulatory approvals including CFIUS clearance were secured.
-
January 12, 2026
- Buyer
- Curi Bio
- Target
- Quvit Bio
- Industry
- Biotechnology
- Location
- South Korea
- Type
- Buyout
Curi Bio completed a full acquisition of South Korea-based Quvit Bio and has established Curi Bio Co., Ltd. as its Asia-Pacific commercial and operational hub. The deal integrates Quvit's imaging hardware, software and team to expand Curi Bio's localized sales, R&D and operational capabilities across South Korea, Japan and China.
-
- Buyer
- Acuitas Therapeutics
- Target
- RNA Technologies & Therapeutics (RNA T&T)
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Buyout
Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.
-
January 8, 2026
- Buyer
- Merck Sharp & Dohme LLC, Merck & Co., Inc.
- Target
- Cidara Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Merck Sharp & Dohme LLC (Merck & Co., Inc.) completed its cash tender offer and follow-on merger to acquire Cidara Therapeutics, Inc. for $221.50 per share, valuing the deal at about $9.2 billion. The acquisition adds Cidara’s late-stage, long-acting, strain-agnostic influenza antiviral candidate CD388 to Merck’s respiratory pipeline.
-
January 6, 2026
- Buyer
- Amgen
- Target
- Dark Blue Therapeutics
- Seller
- Oxford Science Enterprises, Bristol Myers Squibb, Evotec
- Industry
- Biotechnology
- Location
- Oxfordshire, United Kingdom
- Type
- Buyout
Amgen has acquired Dark Blue Therapeutics, an Oxford-based biotechnology company focused on targeted protein degraders for oncology, in a deal valued at up to $840 million including upfront and milestone payments. The acquisition adds Dark Blue's preclinical MLLT1/3 degrader program (DBT-3757) to Amgen's early oncology discovery efforts and will be integrated into Amgen's existing R&D organization.
-
January 6, 2026
- Buyer
- Artis BioSolutions
- Target
- Syngoi Technologies
- Seller
- Oak HC/FT, Columbus Venture Partners
- Industry
- Biotechnology
- Location
- Basque Country, Spain
- Type
- Buyout
Artis BioSolutions has signed a definitive agreement to acquire Syngoi Technologies, a Bilbao, Spain-based biotech developing enzymatic approaches for manufacturing synthetic DNA. The deal is intended to add fast, lower-cost synthetic DNA manufacturing to Artis’ gene-to-drug advanced-therapy platform, with Syngoi’s Bilbao GMP-ready facilities becoming part of Artis’ global footprint.
-
December 15, 2025
- Buyer
- LifeNet Health
- Target
- Tissue Testing Technologies LLC
- Industry
- Biotechnology
- Location
- South Carolina, United States
- Type
- Buyout
LifeNet Health has acquired Tissue Testing Technologies LLC (T3), a North Charleston–based biotechnology firm specializing in biopreservation and cryopreservation solutions. The acquisition adds T3’s proprietary preservation technologies and contract research capabilities to LifeNet Health’s regenerative medicine and transplantation platforms to expand clinical reach and accelerate research pipelines.
-
December 12, 2025
- Buyer
- Genmab A/S, Genmab Holding II B.V.
- Target
- Merus N.V.
- Industry
- Biotechnology
- Location
- Utrecht, Netherlands
- Type
- Buyout
Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.
-
December 9, 2025
- Buyer
- Eli Lilly and Company, Flying Tigers Acquisition Corporation
- Target
- Adverum Biotechnologies, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Eli Lilly and Company agreed to acquire Adverum Biotechnologies in a cash-and-contingent-value-rights tender offer for all outstanding shares. The total consideration is $3.56 per share in cash at closing plus a CVR that could pay up to $8.91 per share upon achievement of specified milestones, with the transaction expected to close in the fourth quarter of 2025.
-
November 27, 2025
- Buyer
- Innova Therapeutics
- Target
- Enci Therapeutics
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Innova Therapeutics has completed the acquisition of Enci Therapeutics, adding Enci’s lead oncology program, IVT-8086, a first-in-class humanized monoclonal antibody targeting SFRP2, to its development pipeline. Financial terms were not disclosed; Innova said the program and associated IP (patents through at least 2042) will support development across multiple solid and hematologic cancers and a companion diagnostic is in development.
-
November 21, 2025
- Buyer
- XOMA Royalty Corporation
- Target
- LAVA Therapeutics N.V.
- Seller
- LAVA Therapeutics N.V. shareholders
- Industry
- Biotechnology
- Location
- Utrecht, Netherlands
- Type
- Buyout
XOMA Royalty Corporation completed the acquisition of all outstanding common shares of LAVA Therapeutics N.V., paying $1.04 per share plus a contingent value right (CVR) that conveys rights to future milestone and royalty proceeds. The deal brings two partnered bispecific antibody programs (with Johnson & Johnson and Pfizer) and additional unpartnered programs into XOMA Royalty's milestone and royalty portfolio as part of its strategy to expand its biotechnology royalty assets.
-
November 7, 2025
- Buyer
- Colossal Biosciences
- Target
- Viagen Pets and Equine
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Buyout
Colossal Biosciences has acquired Viagen Pets and Equine, a Texas-based leader in animal cloning, cryopreservation, and genetic preservation, which will operate as a wholly owned subsidiary under its existing leadership. The deal expands Colossal’s de‑extinction and species preservation platform, bringing Viagen’s cloning expertise, biobanking capabilities and a ~25‑person team into Colossal’s conservation pipeline.
-
November 6, 2025
- Buyer
- NanoTemper Technologies
- Target
- Envue Technologies
- Industry
- Biotechnology
- Location
- Västra Götaland County, Sweden
- Type
- Buyout
NanoTemper Technologies has acquired Envue Technologies, a Swedish spinout that developed Nanofluidic Scattering Microscopy (NSM), to expand its single-molecule and label-free analysis capabilities. The deal integrates Envue's NSM technology into NanoTemper's biophysical analysis portfolio and coincides with NanoTemper's launch of the Dianthus α application to enhance early-stage drug discovery workflows.
-
November 4, 2025
- Buyer
- BioIVT
- Target
- BeCytes Biotechnologies
- Industry
- Biotechnology
- Location
- Catalonia, Spain
- Type
- Buyout
BioIVT has acquired BeCytes Biotechnologies, a Barcelona-based provider of ethically sourced human tissues and primary cell isolation services. The deal expands BioIVT's European footprint and strengthens its capabilities for New Approach Methodologies (NAMs) and ADME research; BeCytes will continue to operate from Barcelona and financial terms were not disclosed.
-
November 4, 2025
- Buyer
- QIAGEN N.V.
- Target
- Parse Biosciences
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
QIAGEN entered into a definitive agreement to fully acquire Parse Biosciences, expanding its Sample technologies portfolio into the single-cell sequencing market. The deal is expected to close in late 2025/December 2025 for an upfront payment of approximately $225 million in cash, plus up to $55 million in milestone payments.
-
November 3, 2025
- Buyer
- Pacific Software, Inc. (dba PurMinds Enterprises, Inc.)
- Target
- PurMinds Holdings Inc., 10763942 Canada, Inc.
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
Pacific Software, Inc. completed a change of control and reverse takeover (RTO) transaction with PurMinds Holdings Inc., finalizing the acquisition effective November 3, 2025 and rebranding the public company as PurMinds Enterprises, Inc. The combined company has taken occupancy of a 20,477 sq. ft. cGMP-ready pharmaceutical manufacturing and R&D facility and is pursuing OTCQX uplisting and PCAOB-audited financials to support its clinical-stage neuromedicine strategy.
-
October 30, 2025
- Buyer
- NewcelX Ltd., NLS Pharmaceutics Ltd., Kadimastem Ltd.
- Target
- NLS Pharmaceutics Ltd., Kadimastem Ltd.
- Industry
- Biotechnology
- Location
- Switzerland
- Type
- Buyout
Swiss-based NLS Pharmaceutics Ltd. merged with clinical-stage cell therapy company Kadimastem Ltd. to create a combined Nasdaq-listed biotechnology company named NewcelX Ltd. The merger closed effective October 30, 2025, with the new company beginning trading on the Nasdaq Capital Market on October 31, 2025 under ticker “NCEL.”
-
October 26, 2025
- Buyer
- Novartis AG
- Target
- Avidity Biosciences, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Novartis AG has entered into a definitive merger agreement to acquire Avidity Biosciences for $72.00 per share in cash, valuing Avidity at approximately $12.0 billion. The transaction follows the planned separation of Avidity’s early-stage precision cardiology programs into a new publicly traded company (“SpinCo”), which is expected to begin trading after the spin-off.
-
October 26, 2025
- Buyer
- Northwest Biotherapeutics, Inc. (NWBio)
- Target
- Advent BioServices Ltd.
- Seller
- Toucan Holdings LLC
- Industry
- Biotechnology
- Location
- United Kingdom
- Type
- Buyout
Northwest Biotherapeutics (NWBio) has completed its acquisition of Advent BioServices Ltd., with Advent becoming a wholly owned subsidiary. The deal is intended to create a more integrated manufacturing and operations platform to scale production of NWBio’s DCVax immunotherapy products, including facilitating consolidation of facilities and reallocation of resources to Sawston and capacity expansion in the United States.
-
October 24, 2025
- Buyer
- Chugai Pharmaceutical Co., Ltd.
- Target
- Renalys Pharma, Inc.
- Industry
- Biotechnology
- Location
- Japan
- Type
- Buyout
Chugai Pharmaceutical Co., Ltd. will acquire Renalys Pharma, Inc. through a definitive stock purchase agreement. The transaction includes an upfront payment of JPY 15.0 billion and potential earn-outs of up to JPY 16.0 billion tied to regulatory and sales milestones for sparsentan in Japan, South Korea, and Taiwan.
-
October 22, 2025
- Buyer
- The Jackson Laboratory
- Target
- New York Stem Cell Foundation (NYSCF)
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
The Jackson Laboratory (JAX) has completed its acquisition of the New York Stem Cell Foundation (NYSCF), combining JAX's genetics and preclinical modeling expertise with NYSCF's stem cell automation and high-throughput research platform. The unified nonprofit aims to create an integrated discovery platform that accelerates translational research by linking genomics, stem cell biology, and data/AI capabilities.
-
October 22, 2025
- Buyer
- Ipsen
- Target
- ImCheck Therapeutics
- Seller
- EQT Life Sciences
- Industry
- Biotechnology
- Location
- France
- Type
- Buyout
Ipsen entered into a definitive share purchase agreement to acquire ImCheck Therapeutics, a Marseille-based next-generation immuno-oncology biotech. The deal includes a €350 million upfront payment and downstream payments, with total potential consideration up to €1 billion, and is expected to close by the end of Q1 2026 subject to regulatory approvals.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.
Frequently Asked Questions
What kinds of assets are buyers acquiring?
Buyers are acquiring a mix of drug candidates and clinical programs, platform technologies and IP, specialist teams and facilities, and manufacturing/service capabilities. Examples: Axol Bioscience bought Newcells’ ophthalmology capabilities; Illumina added proteomics via SomaLogic; Gannet BioChem bought PEG reagent capabilities from Laysan Bio.
Who are the typical buyers in these transactions?
Typical buyers include strategic pharma and platform companies, specialty CDMOs, and financial sponsors. Recurring names appearing on the page include Ampersand Capital Partners, Eli Lilly and Company, and Pfizer Inc., alongside strategic acquirers like Illumina, Sobi, and BioCryst Pharmaceuticals.
Where are these biotechnology deals concentrated geographically?
Many transactions in this set are in the United States (notably Massachusetts, California, Colorado, Alabama and Kentucky), with additional deals in the United Kingdom, France and Quebec, Canada.
How are the deals typically structured or financed?
Structures on the page include stock‑for‑stock deals (e.g., Sensei Biotherapeutics / Faeth Therapeutics), cash plus performance‑based payments (e.g., Illumina / SomaLogic), and combinations of debt facilities and equity issuance (e.g., BioCryst / Astria Therapeutics). Some transactions are accompanied by private placements or follow‑on investments to support development and scale‑up.